Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Recruiting

Phase 1

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Sponsor:

Baylor College of Medicine

Code:

NCT01853631

Conditions

Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2025-03-25.